Search Results - "Steenwyk, R C"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    In vitro evidence for the formation of reactive intermediates of resveratrol in human liver microsomes by Steenwyk, R. C., Tan, B.

    Published in Xenobiotica (01-01-2010)
    “…Resveratrol (3,4′,5-trihydroxystilbene) is a naturally occurring polyphenolic compound found in a variety of foods and over-the-counter health products. It has…”
    Get full text
    Journal Article
  2. 2

    Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine by LASHER, T. A, FLEISHAKER, J. C, STEENWYK, R. C, ANTAL, E. J

    Published in Psychopharmacologia (01-09-1991)
    “…The pharmacokinetic and pharmacodynamic effects of concomitant administration of alprazolam and fluoxetine were studied in this double-blind parallel study in…”
    Get full text
    Journal Article
  3. 3

    Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes by Wienkers, L C, Steenwyk, R C, Sanders, P E, Pearson, P G

    “…Tirilazad mesylate (Freedox), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the treatment of subarachnoid…”
    Get more information
    Journal Article
  4. 4

    Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration by Fleishaker, J C, Peters, G R, Cathcart, K S, Steenwyk, R C

    Published in Journal of clinical pharmacology (01-02-1993)
    “…The multiple dose tolerability and pharmacokinetics of tirilazad mesylate, a 21-aminosteroid free radical scavenger, were assessed in 50 healthy male…”
    Get more information
    Journal Article
  5. 5

    Replacing 14C with stable isotopes in drug metabolism studies by Abramson, F P, Teffera, Y, Kusmierz, J, Steenwyk, R C, Pearson, P G

    Published in Drug metabolism and disposition (01-07-1996)
    “…After administration of a mixed dose of both radioisotope and stable-isotope-labeled tirilazad, we carried out a parallel set of HPLC analyses for drug…”
    Get more information
    Journal Article
  6. 6

    A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine by Wright, C E, Lasher-Sisson, T A, Steenwyk, R C, Swanson, C N

    Published in Pharmacotherapy (01-01-1992)
    “…The influence of fluoxetine on triazolam pharmacokinetics was studied because of changes in diazepam pharmacokinetics reportedly produced by fluoxetine…”
    Get more information
    Journal Article
  7. 7

    Inhibition of in vitro lipid peroxidation by 21-aminosteroids. Evidence for differential mechanisms by Ryan, T P, Steenwyk, R C, Pearson, P G, Petry, T W

    Published in Biochemical pharmacology (01-09-1993)
    “…In a previous report (Ryan and Petry, Arch Biochem Biophys 300: 699-704, 1993), the effects of two 21-aminosteroids (U-74500A and U-74006F) on the oxidation…”
    Get more information
    Journal Article
  8. 8
  9. 9

    In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase by Wienkers, L C, Steenwyk, R C, Mizsak, S A, Pearson, P G

    Published in Drug metabolism and disposition (01-03-1995)
    “…Tirilazad mesylate, a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the treatment of subarachnoid hemorrhage and…”
    Get more information
    Journal Article
  10. 10

    Identification of N-Acetylcysteine Conjugates of 1,2-Dibromo-3-chloropropane: Evidence for Cytochrome P450 and Glutathione Mediated Bioactivation Pathways by Weber, Gregory L, Steenwyk, Rick C, Nelson, Sidney D, Pearson, Paul G

    Published in Chemical research in toxicology (01-06-1995)
    “…The haloalkane 1,2-dibromo-3-chloropropane (DBCP) is a carcinogen, mutagen, nephrotoxin, and testicular toxin. The identification of N-acetylcysteine…”
    Get full text
    Journal Article
  11. 11

    Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2 by Wienkers, L C, Steenwyk, R C, Hauer, M J, Fleishaker, J C, Pearson, P G

    “…Tirilazad mesylate (FREEDOX), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the treatment of subarachnoid…”
    Get more information
    Journal Article